MedTrace Logo

PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation

NCT04170608 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-05-04

Study results available
· View outcomes & findings →

Summary

PEFCAT II: Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

DEVICE

FARAPULSE Endocardial Multi Ablation System

Ablation using the FARAPULSE Endocardial Multi Ablation System

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Petr Neuzil · Nemocnice Na Homolce

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-18
Primary Completion
2020-12-07
Completion
2020-12-07
FDA Device
Yes

Countries

  • Croatia
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170608 on ClinicalTrials.gov